Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011

Fourth quarter sales rose 5% while core[1] operating income grew 17% in constant currencies (cc); full year sales up 12% cc and core operating income up 16% cc Net sales increased 4% (+5% cc) to USD 14.8 ...

Novartis’s Gilenya Pill Reviewed by EU, U.S. After 11 Deaths

European and U.S. regulators are reviewing Novartis AG’s Gilenya pill for multiple sclerosis after reports of 11 deaths among patients who took the drug. The shares fell the most in more than five months.

EU to Review Novartis MS Pill’s Safety After Seven Deaths

The European Medicines Agency started a review of Novartis AG’s Gilenya pill for multiple sclerosis after seven unexplained deaths among patients after beginning treatment.

Novartis’s Gilenya MS Pill Reviewed by EU, U.S. After 11 Deaths

European and U.S. regulators are reviewing Novartis AG’s Gilenya pill for multiple sclerosis after reports of 11 deaths among patients who took the drug. The shares fell the most in almost three months.

Google Drug Sales Settlement Involved Evidence Obtained in Sting Operation

Google’s $500 million settlement with the U.S. government over allegations the company aided illegal online drug sales involved evidence the government obtained during a sting operation, The Wall Street Journal reports.